Efficacy of Aponeurectomy on the 2-year Recurrence Rate of Dupuytren's Disease (REMEDY)

August 23, 2023 updated by: Elsan

Multicenter, Randomized, Open-label Study Evaluating the Efficacy of Aponeurectomy Associated With Adipose Tissue Grafting Compared to Aponeurectomy Alone, on the 2-year Recurrence Rate of Dupuytren's Disease (REMEDY).

Dupuytren's disease is a frequent hereditary disease in Northern Europe. It is a degenerative disease affecting the palmar aponeurosis of the hand. It develops a progressive contractile fibrosis which cuts the hypodermic fatty tissue, adheres to the skin and the phalanges, gradually bending the affected rays, resulting in significant functional impotence.

Various medical and surgical treatments are available.

Study Overview

Detailed Description

Among these treatments, none to date can eliminate recurrences, which are still too frequent.

Open aponeurectomy (consisting of surgical curettage of the fibrotic cords) remains for the moment the reference technique for treating Dupuytren's disease, with recurrences (between 12 and 39%), but less frequent than the needle technique (50 to 85%).

Could the addition of adipose tissue in the resection areas of Dupytren's fibrosis reduce the rate of recurrence (by the inhibitory action of ADCs on myofibroblasts) in addition to reconstructing the hypodermis in the cavity left by the resection of the cords and improving the quality of the scars? The investigators insist on the fact that this is a homotopic and homologous adipose tissue graft, in closed circuit without denaturation or adjuvant products.

Since, to our knowledge, no other team has used "lipofilling" as an adjuvant treatment to the open resection technique of Dupuytren's cords (aponeurectomy), the investigators first conducted a clinical feasibility and safety study on 70 patients between 2012 and 2017 (currently being published by Springer Editions).

The investigators now wish to conduct a prospective comparative study between patients operated by aponeurectomy WITH (experimental group) and WITHOUT (control group) addition of autologous adipose tissue in the resection areas of Dupuytren's cords.

Study Type

Interventional

Enrollment (Estimated)

150

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Mulhouse, France, 68100
        • Not yet recruiting
        • Clinique du Diaconat
        • Contact:
          • Chihab TALEB, MD
          • Phone Number: 03 89 70 34 70
      • Pessac, France, 33600
        • Recruiting
        • Institut Aquitain de la Main
        • Contact:
        • Contact:
        • Principal Investigator:
          • Elias Sawaya, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Age ≥ 18 years
  • Carrier of Tubiana stage II-IV Dupuytren's disease on at least one or more rays, not previously operated
  • Indication of a surgery by aponeurectomy
  • Skin pinch of the posterior aspect of the arm of more than 1cm
  • Affiliation to a social security system
  • Patient informed of the study and having given informed consent

Exclusion Criteria:

  • Previous surgery of any kind for Dupuytren's disease
  • Involvement on the thumb only
  • Need for a total skin graft or a pedicle flap on all the rays to be treated
  • Active autoimmune disease
  • Previous treatment with collagenase
  • Pregnant and breastfeeding women
  • Patient under legal protection
  • Contraindications to MRI (criteria applicable only for patients from the coordinating center, not applicable for other centers)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Aponeurectomy with grafting
The experimental group evaluates the aponeurectomy associated with adipose tissue grafting.

The lipofilling is performed, once the incisions are closed and is performed with the Puregraft® system.

The fat graft is taken from the posterior, medial and anterior sides of the arm, by skin puncture. Approximately 10 cc are harvested, allowing a reinjection of about 2 cc per digital radius treated. After conditioning, the fat graft is redistributed to the curettage areas through the skin incisions.

Active Comparator: Aponeurectomy alone
The control group evaluates the aponeurectomy alone.
The patient is installed in dorsal decubitus position and the arm to be treated is anesthetized by axillary block. The procedure is performed in the operating room, respecting all the rules of asepsis and safety in force. A tourniquet is placed on the arm to be treated and inflated to 250mmHg. Broken incisions are then made opposite the cords to be excised, which are located by palpation. Once the noble elements have been identified, the excision of the cords and fibrous nodules can be done as completely as possible. Sometimes an arthrolysis procedure is necessary in order to restore extension to a joint that has been fixed in a flexion position for several years. Skin closure is most often possible by direct suture or by means of local fatty skin flaps. In some cases, the surgeon may use total skin grafts, or directed healing in certain areas where direct skin suture is not possible.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
2-year recurrence rate of Dupuytren's disease
Time Frame: 2 Years after intervention
Recurrence being defined as follows: appearance, at 2 years post-op compared to 6 weeks post-op, of a contracture of more than 20 degrees, with palpable cord, on any treated joint.
2 Years after intervention

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
3-year recurrence rate in both groups
Time Frame: 3 Years after intervention
Recurrence being defined as follows: Appearance of a contracture of more than 20 degrees, with palpable cord, on any treated joint, at 3 years post-op compared to 6 weeks post-op
3 Years after intervention
5-year recurrence rate in both groups
Time Frame: 5 Years after intervention
Recurrence being defined as follows: Appearance of a contracture of more than 20 degrees, with palpable cord, on any treated joint, at 5 years post-op compared to 6 weeks post-op
5 Years after intervention
Comparison of the appearance of scars in both groups
Time Frame: 1 Year after intervention
Use of questionnaire The Patient and Observer Scar Assessment Scale (POSAS). This questionnaire consists of 2 separate scales of 6 items each (one scale for the observer and one scale for the patient). Each item is evaluated on 10 points. The lowest score is "1" which corresponds to the appearance of normal skin. A score of 10 indicates the greatest deviation from normal skin. The total score for each of the scales is obtained by adding the score for each of the 6 items. This total score can vary between 6 and 60 for each of the scales.
1 Year after intervention
Comparison of the appearance of scars in both groups
Time Frame: 2 Years after intervention
Use of questionnaire The Patient and Observer Scar Assessment Scale (POSAS). This questionnaire consists of 2 separate scales of 6 items each (one scale for the observer and one scale for the patient). Each item is evaluated on 10 points. The lowest score is "1" which corresponds to the appearance of normal skin. A score of 10 indicates the greatest deviation from normal skin. The total score for each of the scales is obtained by adding the score for each of the 6 items. This total score can vary between 6 and 60 for each of the scales.
2 Years after intervention
Comparison of the complication rates in both groups
Time Frame: 1 Week after intervention
Complications are defined as Hematoma, infection, graft lysis, disunion or nerve damage.
1 Week after intervention
Comparison of the complication rates in both groups
Time Frame: 6 Weeks after intervention
Complications are defined as Hematoma, infection, graft lysis, disunion or nerve damage.
6 Weeks after intervention
Comparison of the rate of occurrence of algodystrophy, regardless of cause
Time Frame: 1 Year after intervention
Collection of information on the occurrence of algodystrophy, considered as Adverse Event of Special Interest.
1 Year after intervention
Comparison of the rate of occurrence of algodystrophy, regardless of cause
Time Frame: 2 Years after intervention
Collection of information on the occurrence of algodystrophy, considered as Adverse Event of Special Interest.
2 Years after intervention
Comparison of the rate of occurrence of algodystrophy, regardless of cause
Time Frame: 3 Years after intervention
Collection of information on the occurrence of algodystrophy, considered as Adverse Event of Special Interest.
3 Years after intervention
Comparison of the rate of occurrence of algodystrophy, regardless of cause
Time Frame: 5 Years after intervention
Collection of information on the occurrence of algodystrophy, considered as Adverse Event of Special Interest.
5 Years after intervention
Evaluation of hypodermic fat volume loss
Time Frame: 1 Year after intervention

Measurement of hypodermal fat thickness on MRI for five patients of experimental group, only include in the coordinating center.

The evolution is measured with preoperative, immediate postoperative (day of surgery) and 1-year MRI.

1 Year after intervention
Comparison of the effect on quality of life in both groups
Time Frame: 6 Weeks after intervention
Use of Quick Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire. The score consists of 11 questions that assess the function of the upper limb for the gestures of daily life. The final score is between 0 and 100, with 0 corresponding to normal function, and 100 to almost no function.
6 Weeks after intervention
Comparison of the effect on quality of life in both groups
Time Frame: 1 Year after intervention
Use of Quick Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire. The score consists of 11 questions that assess the function of the upper limb for the gestures of daily life. The final score is between 0 and 100, with 0 corresponding to normal function, and 100 to almost no function.
1 Year after intervention
Comparison of the effect on quality of life in both groups
Time Frame: 2 Years after intervention
Use of Quick Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire. The score consists of 11 questions that assess the function of the upper limb for the gestures of daily life. The final score is between 0 and 100, with 0 corresponding to normal function, and 100 to almost no function.
2 Years after intervention
Comparison of the effect on quality of life in both groups
Time Frame: 5 Years after intervention
Use of Quick Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire. The score consists of 11 questions that assess the function of the upper limb for the gestures of daily life. The final score is between 0 and 100, with 0 corresponding to normal function, and 100 to almost no function.
5 Years after intervention
Evaluation of the safety of aponectomy surgery associated or not with adipose tissue grafting
Time Frame: 6 Weeks after intervention
Collection of adverse events
6 Weeks after intervention
Evaluation of the primary endpoint on the second hand operated on.
Time Frame: Within five years after intervention

The surgery being done with or without fat according to the treatment of the 1st randomized hand (cross-over scheme).

Data collection for the second surgery only if it occurs between the 1st hand surgery and the patient's protocol discharge.

Within five years after intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Elias SAWAYA, MD, Institut Aquitain de la Main

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 13, 2022

Primary Completion (Estimated)

June 1, 2024

Study Completion (Estimated)

June 1, 2029

Study Registration Dates

First Submitted

September 24, 2021

First Submitted That Met QC Criteria

September 24, 2021

First Posted (Actual)

October 5, 2021

Study Record Updates

Last Update Posted (Actual)

August 24, 2023

Last Update Submitted That Met QC Criteria

August 23, 2023

Last Verified

August 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Dupuytren's Disease

Clinical Trials on Aponeurectomy with grafting

3
Subscribe